Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07804810) titled 'Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Shanghai Minwei Biotechnology Co., Ltd
Condition:
Overweight , Obesity
Intervention:
Drug: MWN105 1
Drug: MWN105 2
Drug: MWN105 3
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 3, 2025
Target Sample Size: 120
Countries of Recruitment:
China
To know more, visit https://clin...